Background: A potential association between proton-pump inhibitors (PPIs) and gastric cancer (GC) remains undefined. Thus, we aimed to evaluate such association within the Stomach cancer Pooling (StoP) Project. Methods: Data from five case-control studies of the StoP Project were included (1,889 cases, 6,517 controls). We assessed the impact of different exposure definitions, specifically any reported use of PPIs and exposure definitions based on the duration of PPI intake. Additionally, we modelled the dose-response relationship between cumulative duration of PPI intake and GC. Results: Significant associations between PPI intake and GC, both overall and in the stratified analyses, were limited to exposure definitions based on short durations of intake. The overall OR for any reported PPI intake was 1.78 (95% CI: 0.76, 4.14). In the dose-response analysis, the ORs of GC were found to be higher for short durations of PPI intake (six months: OR 3.26 [95% CI: 2.40, 4.42], one year: OR 2.14 [95% CI: 1.69, 2.70], two years: OR 1.50 [95% CI: 1.22, 1.85], three years: OR 1.27 [95% CI: 1.03, 1.56]), with the association becoming not significant for durations longer than three years. Conclusions: Our findings suggest that the observed association between PPIs and GC might be mainly due to reverse causality. Impact: The results of this study suggest that PPIs are a safe therapeutic choice regarding their effect on the occurrence of GC.

Intake of Proton-Pump Inhibitors and Gastric Cancer Within the Stomach cancer Pooling (StoP) Project / M. Sassano, M. Mariani, C. Pelucchi, N. Lunet, S. Morais, V. Martín, V. Moreno, M.P. Curado, E. Dias-Neto, M. Leja, E. Gašenko, C. La Vecchia, S. Boccia, R. Pastorino. - In: CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION. - ISSN 1055-9965. - 32:9(2023 Sep 01), pp. 1174-1181. [10.1158/1055-9965.EPI-23-0241]

Intake of Proton-Pump Inhibitors and Gastric Cancer Within the Stomach cancer Pooling (StoP) Project

C. Pelucchi;C. La Vecchia;
2023

Abstract

Background: A potential association between proton-pump inhibitors (PPIs) and gastric cancer (GC) remains undefined. Thus, we aimed to evaluate such association within the Stomach cancer Pooling (StoP) Project. Methods: Data from five case-control studies of the StoP Project were included (1,889 cases, 6,517 controls). We assessed the impact of different exposure definitions, specifically any reported use of PPIs and exposure definitions based on the duration of PPI intake. Additionally, we modelled the dose-response relationship between cumulative duration of PPI intake and GC. Results: Significant associations between PPI intake and GC, both overall and in the stratified analyses, were limited to exposure definitions based on short durations of intake. The overall OR for any reported PPI intake was 1.78 (95% CI: 0.76, 4.14). In the dose-response analysis, the ORs of GC were found to be higher for short durations of PPI intake (six months: OR 3.26 [95% CI: 2.40, 4.42], one year: OR 2.14 [95% CI: 1.69, 2.70], two years: OR 1.50 [95% CI: 1.22, 1.85], three years: OR 1.27 [95% CI: 1.03, 1.56]), with the association becoming not significant for durations longer than three years. Conclusions: Our findings suggest that the observed association between PPIs and GC might be mainly due to reverse causality. Impact: The results of this study suggest that PPIs are a safe therapeutic choice regarding their effect on the occurrence of GC.
proton pump inhibitors; stomach neoplasms; gastric cancer; case-control studies; epidemiologic biases;
Settore MED/01 - Statistica Medica
Settore MED/06 - Oncologia Medica
Settore MED/12 - Gastroenterologia
Settore MED/42 - Igiene Generale e Applicata
Settore MED/49 - Scienze Tecniche Dietetiche Applicate
   Advancing aetiology and prevention of gastric cancer: 5-year development of the Stomach cancer Pooling (StoP) Project (5° anno)
   StoP
   FONDAZIONE AIRC PER LA RICERCA SUL CANCRO ETS
   AIRC IG 2018- ID 21378
1-set-2023
26-giu-2023
Article (author)
File in questo prodotto:
File Dimensione Formato  
Proton pump_Sassano STOP.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 1.76 MB
Formato Adobe PDF
1.76 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/980570
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 1
social impact